GLAXO U.S. SALES GROWTH SLOWS TO 3% FOR SECOND HALF OF 1994; U.S. SALES TOTAL $1.91 BIL.; DISCOUNTING REDUCES WORLDWIDE ZANTAC SALES 4% TO $1.78 BIL.
Glaxo's U.S. sales rose 3% for the six months ended Dec. 31 compared to the year-earlier period as U.S. sales totaled [pound]1.22 bil. ($1.91 bil.), according to interim results announced Feb. 7
You may also be interested in...
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.